Please provide your email address to receive an email when new articles are posted on . The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran plus an ...
Please provide your email address to receive an email when new articles are posted on . Among patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart/elebsiran, which rose to 46% ...
VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported In the majority of ...
Professor of Medicine and Chief, Division of Hepatology, Center for Liver Disease, University of Miami School of Medicine, Miami, Florida Antiviral studies generally used intermediate markers of ...
Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in cancer patients with chronic HBV (hepatitis B surface antigen [HBsAg] positive) undergoing cytotoxic chemotherapy ...
Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results